MAM
BMRN icon

Martingale Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Martingale Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,878
Closed -$3.58M – 770
2024
Q3 		$3.58M Sell
50,878
-7,060
-12% -$590K 0.08% 189
2024
Q2 		$4.77M Sell
57,938
-9,666
-14% -$805K 0.1% 165
2024
Q1 		$5.9M Sell
67,604
-4,650
-6% -$416K 0.12% 153
2023
Q4 		$6.97M Sell
72,254
-9,189
-11% -$813K 0.14% 149
2023
Q3 		$7.21M Sell
81,443
-8,949
-10% -$796K 0.15% 147
2023
Q2 		$7.84M Sell
90,392
-5,417
-6% -$510K 0.15% 148
2023
Q1 		$9.32M Buy
95,809
+4,949
+5% +$513K 0.18% 147
2022
Q4 		$9.4M Buy
90,860
+7,168
+9% +$673K 0.18% 143
2022
Q3 		$7.09M Buy
83,692
+5,779
+7% +$515K 0.14% 150
2022
Q2 		$6.46M Buy
77,913
+22,447
+40% +$1.79M 0.12% 166
2022
Q1 		$4.28M Buy
55,466
+14,833
+37% +$1.24M 0.06% 189
2021
Q4 		$3.59M Buy
40,633
+17,300
+74% +$1.43M 0.05% 207
2021
Q3 		$1.8M Buy
+23,333
New +$1.84M 0.02% 336
2021
Q2 		– Sell
-10,912
Closed -$824K – 834
2021
Q1 		$824K Buy
+10,912
New +$891K 0.01% 475
2020
Q3 		– Sell
-39,763
Closed -$4.91M – 1029
2020
Q2 		$4.91M Buy
+39,763
New +$3.95M 0.06% 313

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Martingale Asset Management's BMRN Position: Q4 2024 in Review

Martingale Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 50,878 shares — an estimated $3.58M sold.

Martingale Asset Management first reported a position in BMRN in Q2 2020 and held it in 15 quarters. The position peaked at $9.4M in Q4 2022. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

  • Martingale Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Martingale Asset Management sold 50,878 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $3.58M.
  • Martingale Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • Martingale Asset Management's BioMarin Pharmaceuticals position peaked at $9.4M in Q4 2022.
  • 543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on Martingale Asset Management's 13F filing for Q4 2024, filed 13 Feb 2025.